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Challenges and Caveats for stents of New 
Technology: Which stent is better? What 
are the results in high – risk patients?
Anastasios Salahas, MD
Coronary stenting has revolutionized percutaneous coronary revascularization. 
Two landmark studies published in 1994, Benestent and STRESS, demonstrated the 
significantly superior outcomes of intracoronary stenting versus balloon angioplasty 
[1,2]. However, the success of bare–metal stents was limited by the occurrence of 
neointimal hyperplasia (NIH) leading to in–stent restenosis (ISR). The problem of 
neointimal hyperplasia, as measured by late loss, represented a significant hurdle, 
limiting the long-term patency of stents in many patient populations. The solution to 
the problem of ISR (the Achilles heel of the stent) was given by the evolution of new 
stent platforms coated with polymers eluting anti-proliferative drugs, drug eluting 
stents-DES.
The therapeutic objective of using a drug – eluting stent is to inhibit the excessive 
neointimal proliferation post – stenting that is responsible for late loss, leading to 
restenosis and an increased risk of reintervention. The original pivotal trials of the 
drug eluting stents SIRIUS (sirolimus – eluting stent) and TAXUS IV (paclitaxel 
– eluting stent) did indeed show significant reductions in restenosis and target lesion 
revascularization (TLR) rates compared to bare metal stents (Figures 1, 2) [3,4].
Thus, drug – eluting stents (DES) have been enthusiastically adopted by inter-
ventional cardiologists worldwide triggering an interest for the conduction of new 
studies assessing their performance in high – risk populations and in ever – more 
complex lesions. Patients with small vessels (<2-8 mm) [5,6], bifurcation lesions 
[7,8], long lesions [9,10], chronic total occlusions [11], diabetic patients [10,12], and 
patients with multivessel coronary artery disease have been randomized to compara-
tive studies with BMS and have shown a remarkable reduction of TLR and in-stent 
binary restenosis.
These beneficiary results have increased the body of clinical evidence and broad-
ened the spectrum of their indications and use in interventional cardiology even in 
patients with unprotected left main stem disease. In a recent study Valgimigli M et 
al concluded that when percutaneous intervention is undertaken at left main lesions, 
routine DES implantation reduces the cumulative incidence of myocardial infarction 
and the need of target vessel revascularization compared with the BMS [14].
Since March 2003 both DES Cypher (SES) (Cordis/J+J) and Taxus PES (Boston 
Scientific) have been commercially available worldwide. Both stent platforms elute 
anti–proliferative drugs with comparative reductions of TLR and binary restenosis 
in the aforementioned studies and it may appear reasonable to consider both DES to 
be equivalent on the basis of class effect. However, there are a number of significant 
differences in both stent platform and drug which make it far from certain that SES 
and PES are actually clinically equivalent.
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FIGURE 1. Results of the SIRIUS trial [3].
FIGURE 2. Results of the TAXUS trial [4].
More recently we have had the opportunity to compare the 
two commercially available DES following the presentation 
of data from head to head comparisons. In a meta–analysis 
study Kastrati et al concluded that SES-Cypher outperforms 
PES–Taxus in terms of clinical and angiographic restenoses 
rates [15]. However other studies do not confirm this supe-
riority [16,17].
So the question “which stent is better”? is up to now dif-
ficult to answer so the issue it’s rather rhetorical. It remains 
to be answered in the future.
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